ZEGFROVY — 2467017
Application number
2467017
Type(s)
Design
Category
Trademark
CIPO Status
FORMALIZED
TM5 status
LIVE/APPLICATION/
Awaiting Examination
The trademark application has been accepted by the Office (has met the minimum filing requirements) and has not yet been assigned to an examiner.
Filed
2026-04-02
Current owner
AstraZeneca UK Limited
1 Francis Crick Avenue, Cambridge Biomedical Campus
Cambridge, CB2 0AA
UNITED KINGDOM
Agent
LEI ZHOU
(WITMART INC)
18 King Street East, Suite 1400
Toronto
ONTARIO M5C1C4
Applicant
Dizal Pharmaceutical Co., Ltd.
Rm.404, 405, 416,Building C,Huirong Square,No.26 Hefeng Road,Xinwu District
Wuxi, Jiangsu Province,
CHINA
Old Owner
Dizal Pharmaceutical Co., Ltd.
Rm.404, 405, 416,Building C,Huirong Square,No.26 Hefeng Road,Xinwu District
Wuxi, Jiangsu Province,
CHINA
Documents
Index headings
- ZEGFROVY
Vienna information (Code & Description)
- 26.4.4
- Other irregular parallelograms, trapezia and quadrilaterals, quadrilaterals containing one or more rounded corners
- 26.4.9
- Several quadrilaterals juxtaposed, joined or intersecting
- A 26.4.24
- Quadrilaterals with dark surfaces or parts of surfaces
- 26.1.2
- Ellipses
- A 26.1.24
- Circles or ellipses with dark surfaces or parts of surfaces
Foreign Character Translation
"ZEGFROVY" is a coined term and has no meaning in English or French.
Goods (Nice class & Statement)
- 5
- (1) Anti-cancer preparations; antitumor drugs; antivirals; biological preparations made from human blood cells for cell therapy; biopharmaceuticals for the treatment of cancer; chemotherapeutics; diagnostic chemical reagents for medical purposes; drug delivery agents in the form of dissolvable tablets that provide rapid release of the active ingredients for a wide variety of pharmaceuticals; excipients for use in pharmaceuticals to treat cancer; human pharmaceuticals for treatment of cancer; injectable preparations made of solutions of hyaluronic acid for medical and pharmaceutical purposes; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for the treatment of interstitial lung disease (ILD); pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for use in chemotherapy; pharmaceutical products for the treatment of cancer; tumor suppressing agents
Recordals (known also as Footnotes)
CHANGE IN TITLE / CHANGEMENT EN TITRE: TYPE OF CHANGE / GENRE DE CHANGEMENT: Assignment / Cession DATE REGISTERED / DATE DE L'ENREGISTREMENT: 2026-10-13 DATE OF CHANGE / DATE DE CHANGEMENT: 2026-10-12 COMMENTS / COMMENTAIRES: FROM/DE: Dizal Pharmaceutical Co., Ltd. TO/A: AstraZeneca UK LimitedAction History
| Action | Action date | Due date | Comments |
|---|---|---|---|
| Filed | 2026-04-02 | ||
| Created | 2026-04-02 | ||
| Formalized | 2026-04-02 | ||
| Change of Title Registered | 2026-10-13 | Assignment/Cession |